148 related articles for article (PubMed ID: 9443475)
1. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease.
Tapiola T; Lehtovirta M; Ramberg J; Helisalmi S; Linnaranta K; Riekkinen P; Soininen H
Neurology; 1998 Jan; 50(1):169-74. PubMed ID: 9443475
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
4. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
5. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
[TBL] [Abstract][Full Text] [Related]
6. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
7. Tau protein in cerebrospinal fluid from semantic dementia patients.
Andersen C; Froelich Fabre S; Ostberg P; Lannfelt L; Wahlund L
Neurosci Lett; 2000 Nov; 294(3):155-8. PubMed ID: 11072138
[TBL] [Abstract][Full Text] [Related]
8. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease.
Arai H; Higuchi S; Sasaki H
Gerontology; 1997; 43 Suppl 1():2-10. PubMed ID: 9187933
[TBL] [Abstract][Full Text] [Related]
10. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.
Skoog I; Vanmechelen E; Andreasson LA; Palmertz B; Davidsson P; Hesse C; Blennow K
Neurodegeneration; 1995 Dec; 4(4):433-42. PubMed ID: 8846237
[TBL] [Abstract][Full Text] [Related]
11. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.
Andreasen N; Minthon L; Clarberg A; Davidsson P; Gottfries J; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
Neurology; 1999 Oct; 53(7):1488-94. PubMed ID: 10534256
[TBL] [Abstract][Full Text] [Related]
13. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up.
Blomberg M; Jensen M; Basun H; Lannfelt L; Wahlund LO
Neurosci Lett; 1996 Aug; 214(2-3):163-6. PubMed ID: 8878109
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
Lasser RA; Dukoff R; Levy J; Levin R; Lehtimäki T; Seubert P; Sunderland T
Int J Geriatr Psychiatry; 1998 Nov; 13(11):767-74. PubMed ID: 9850873
[TBL] [Abstract][Full Text] [Related]
15. Increased CSF cortisol in AD is a function of APOE genotype.
Peskind ER; Wilkinson CW; Petrie EC; Schellenberg GD; Raskind MA
Neurology; 2001 Apr; 56(8):1094-8. PubMed ID: 11320185
[TBL] [Abstract][Full Text] [Related]
16. Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease.
Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Matsushita S; Machida N; Nakagawa T; Lee VM; Trojanowski JQ; Sasaki H
J Am Geriatr Soc; 1997 Oct; 45(10):1228-31. PubMed ID: 9329486
[TBL] [Abstract][Full Text] [Related]
17. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
[TBL] [Abstract][Full Text] [Related]
18. ApoE alleles and tau markers in patients with different levels of cognitive impairment.
Lavados M; Farías G; Rothhammer F; Guillon M; Mujica MC; Maccioni C; Maccioni RB
Arch Med Res; 2005; 36(5):474-9. PubMed ID: 16099324
[TBL] [Abstract][Full Text] [Related]
19. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
20. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.
Itoh N; Arai H; Urakami K; Ishiguro K; Ohno H; Hampel H; Buerger K; Wiltfang J; Otto M; Kretzschmar H; Moeller HJ; Imagawa M; Kohno H; Nakashima K; Kuzuhara S; Sasaki H; Imahori K
Ann Neurol; 2001 Aug; 50(2):150-6. PubMed ID: 11506396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
